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Abstract
Children and adolescents with inflammatory bowel disease (IBD) tend to have more extensive and
severe disease than adults. IBD presenting in childhood interferes with growth, education and
employment as well as psychosocial and sexual development, frequently delaying adolescent
developmental milestones. Transition, in the context of healthcare, is the purposeful, planned
movement of adolescents and young adults with chronic physical and medical conditions to adult-
orientated healthcare systems. Although no single model has been widely adopted and despite a
paucity of data, recent guidelines from Europe and the USA propose the formation of specialist
transition clinics for adolescent patients with IBD. In order to develop a successful transition service,
the barriers that arise because of differences between paediatric and adult IBD services need to be
identified. In this article, we review the concept of transitional care for adolescents with IBD,
highlighting the important differences in not only, paediatric and adult IBD, but also paediatric and
adult IBD services. We consider the consequences of failed transition, and describe the limited
published data reporting different approaches to transition in IBD, before outlining our own approach.
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The incidence of IBD presenting in children is increasing,
more than 25% cases are now diagnosed under the age of
16.1–4 Inflammatory bowel disease (IBD) presenting at this
age is more extensive and severe than in adults.5–9 It
interferes with growth, education and employment as well as
psychosocial and sexual development.10 Adolescents have
traditionally been transferred from paediatric to adult care
at the age of 16 regardless of their maturity, pubertal stage
or growth velocity. However, following political directives
stating that the transfer of care must be clearly defined and
planned for all childhood illnesses,11 and in response to
lobbying by patient organisations, recent guidelines from
Europe12 and the USA13,14 recommend the formation of
specialist adolescent transition clinics.
Although well developed in other chronic childhood
diseases such as diabetes and cystic fibrosis, adolescent
clinics in IBD are in their infancy. Here we review the concept
of transitional care for adolescents highlighting the impor-
tant differences both between paediatric and adult IBD, and
also paediatric and adult IBD services. We discuss the barriers
to seamless transfer and both our own and alternative
models for transition care.
2. Adolescence and transition
2.1. Adolescence
Adolescence literally means to grow up and describes the
period of pubertal, emotional and cognitive developmentthat occurs between the onset of puberty and adulthood.15
Physiologically, adulthood is defined by the acquisition of
secondary sexually characteristics and fecundity, usually
occurring between 11 and 15 years of age. Psychologically
the onset of adulthood is more difficult to define and
probably differs according to gender: girls typically mature
at a younger age than boys. Early adolescence (10–12 years)
is characterised by pubertal development, middle adoles-
cence (13–15 years) by psychosocial independence and late
adolescence (16–18 years) by the development of personal
identity, life aspirations and goals, as well as ethical and
moral values.16,17 In everyday terms, though, there is no age
cut-off and different adolescent developmental milestones
may be reached at different times.2.2. Age-adjusted expectations in chronic disease
In early adolescence, individuals can be expected to describe
their condition, to name medications and doses, to discuss
the role of their family, teachers, peer groups and
themselves in their care, as well as consider the impact of
their disease on school attendance and academic aspira-
tions. By the end of adolescence individuals should be
capable of making informed therapeutic decisions; to be able
to book and attend appointments and investigations; to
maintain an awareness of their sexual fecundity and the need
for contraception; and to plan ahead and use the service in a
flexible way.16 In addition they are expected to take on the
administrative roles previously carried out by their parents,
which may include organising their own healthcare insur-
ance18 (Fig. 1).
Figure 1 Adolescent milestones, transition and transfer of care. A schematic diagram that demonstrates the differences between
transition and transfer with the milestones that patients may be expected to reach at each stage.
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Transition, in the context of healthcare, can be defined as
the purposeful, planned movement of adolescents with
chronic physical and medical conditions to adult-orientated
healthcare systems.19 Transition should be uninterrupted,
coordinated and matched to the developmental abilities of
the individual.17 Transfer is the point of handover to the
adult healthcare team, and should be considered part of, and
not necessarily the end of transition (see Fig. 1).3. Childhood compared with adult onset IBD
Although beyond the scope of this review, there are
important differences in the incidence, presentation, clin-
ical phenotype andmanagement of IBD between children and
adults that need to be taken into account when planning an
IBD transition service.3.1. Incidence
The incidence of UC in the UK is 13.9/100000 new diagnoses
per year; Crohn's disease is less common with 8.3/100000.20
Overall more than 25% cases of IBD are now diagnosed under
the age of 16.1,2 The paediatric incidence of UC in the UK is
1.3/100000, and in contrast to adults, Crohn's disease is
more common with 2.5/100000 new diagnoses per year.21
However, more recent studies from Finland report a much
higher incidence in paediatric clinics (CD 5/100 000, UC
9/100 000).3 Adult incidence rates in the UK appear to be
stable,22 in contrast incidence rates in children are increas-
ing,3,4,23 suggesting an increasing requirement for transition
care in IBD in the future.3.2. Phenotype
Data from well-designed adequately powered cohort studies
confirm that children and adolescents with IBD are more likely
to have Crohn's disease (CD) than ulcerative colitis (UC): both
diseases tend to be more extensive and severe at diagnosis and
more likely to extend in the first 3 years than in adults.5,6 Upper
gastro-intestinal (GI) involvement is often cited as being more
common in paediatric IBD than in adults.24–27 Unfortunately,
little data is available for adults with IBD, as until recently
upper GI endoscopy has not been routinely undertaken.
3.3. Presentation
Arguably the most important difference between adults and
children with IBD is the potential for growth failure and/or
pubertal delay. At presentation 10–40%28,29 of children have
anthropomorphic evidence of growth failure in part due to
anorexia and malabsorption but also resulting from a direct
effect of intestinal inflammation.30
3.4. Management
In view of the patients' age, disease extent at presentation and
crucial relevance of growth and puberty in the adolescent with
IBD, several management issues are specific to this patient
population. Therapeutic strategies to induce remission which
include corticosteroids can have a significant negative impact
on growth velocity.29 Therefore in Europe, an exclusive liquid
diet is recommended as induction therapy for Crohn's disease
to avoid the negative impact of steroids on growth.12,31
However, steroids remain the mainstay of induction therapy
for 5 ASA refractory or severe, ulcerative colitis and for Crohn's
disease in North America. In view of concerns regarding the
impact of corticosteroids on body image, especially in teenage
512 J. Goodhand et al.girls,32 adult gastroenterologists may come across significant
resistance to further courses of steroids, and patients who
have already taken exclusive enteral nutrition may subse-
quently request it during relapse. The extensive disease at
presentation and the potential long duration of IBD in
adolescents often mandate early use of disease modifying
immunosuppressive medications such as azathioprine and
biologic therapy.12 Furthermore, recent evidence in both CD
and UC suggests that combination therapy with both a
thiopurine and an anti TNF antibody is more effective than
monotherapywith either agent alone (although these trials did
not include patients under the age of 21).33,34 The potential
side effects of this strategy such as opportunistic infections
and malignancy need to be discussed with all patient groups.
However, these risks are not equal in all age groups and the risk
of opportunistic infections increases with age.35 In contrast,
the case reports of hepato-splenic T cell lymphoma in patients
with CD receiving combination therapy suggest that this fatal
complication is more common in young men.36 In addition,
medical and surgical strategies may impact on both fertility
and fecundity which have particular relevance to adolescent
patients.12,37 Thus both the benefits and the risks of individual
therapeutic strategies are different in the adolescent com-
pared to the adult patient.3.5. Quality of life
IBD diagnosed during childhood leads to behavioural adapta-
tions that interfere with psychosocial and sexual development,
education and employment. Psychological adjustment not only
to the diagnosis of a life-long disorder but also to the
uncertainty of the relapse-remission cycle depends on an
individual's coping resources.38 Although the mechanisms
underlying psychological distress and depression in IBD are
complex,39 longitudinal studies in adults,40,41 report a positive
relationship with disease activity. The combination of intrusive
gastrointestinal symptoms, corticosteroid exposure and the
release of centrally active pro-inflammatory cytokines result in
adolescents with IBD reporting poorer quality of life (QOL)
scores and having a higher prevalence of psychological distress,
in particular depression than unaffected peers.42,43 Unfortu-
nately comparative studies between children and adults in IBD
have not been undertaken, though it seems likely, given the
extent and inflammatory nature of their disease, that
adolescents will suffer more. Avoidant coping (where an
individual distracts themselves with social diversion) to deal
with stress, is more commonly employed by adolescents with
IBD than their peers.44 This behaviour may be associated with
disease relapse in patients with quiescent disease.45
Therefore, an adult gastroenterologist will inherit adoles-
cent patients with complex and extensive disease, often with
ongoing active inflammation that is refractory to medical
treatments, not easily amenable to surgery, and frequently
complicated by growth failure and significant psychological
distress. The risks and benefits of individual therapeutic
strategies differ for adolescent patients compared with the
conventional adult population. Unfortunately traditional adult
services are not well suited to serve this complex group of
patients andwhen planning their care it is important to consider
differences between paediatric and adult IBD services as they
may lead to significant barriers to patient transfer (see Table 1).4. Paediatric versus adult IBD services
4.1. Geographical constraints
Paediatric gastroenterologists caring for patients with IBD
are usually clustered together in tertiary centres. In the UK,
there are 26 such centres; 10 are linked to academic posts
with access to novel drug treatments.46 Traditional transi-
tion then, as well as being ideological is often geographical
with adolescent frequently being discharged back to their
local referral centre at 16.
4.2. Specialist skills
Adult gastroenterologists have different skill sets to paedi-
atricians; few have been trained to assess growth velocity or
to evaluate pubertal stage, and when questioned only about
half felt competent to do so.47 In non-academic centres, IBD
patients are commonly seen in general gastroenterology
clinics, and often by physicians without a sub-specialty
interest in IBD. In a UK national questionnaire survey,
paediatric gastroenterologists highlighted a lack of interest
and specialist training in the receiving adult gastroenterol-
ogist as a significant barrier to transition.48
4.3. Outpatient services
There are also marked differences between paediatric and
adult outpatient clinics that children diagnosed with IBD need
to adapt to during the transition to adult care. Paediatric clinics
are typically family-focused; appointments are more frequent
and typically longer than permitted in adult care. A multi-
disciplinary approach, including specialist nurses, dieticians,
clinical psychologists, pharmacists and the medical team are
usually available. Multidisciplinary clinics, by contrast, are less
well established for adults, at least in the UK.46
4.4. Inpatient and endoscopy services
Inpatient infrastructure is vastly different between paediat-
ric services, where wards are age-specific, compared with
adult services where the majority of patients are elderly.
This is a serious issue for young patients admitted to the
adult wards for the first time. In addition, their parents may
not be allowed to stay overnight on the ward with them as
they had been used to whilst in the paediatric service.
Finally, most endoscopic investigations are performed under
general anaesthetic in children. In contrast, the vast
majority of adult procedures occur under conscious or no
sedation, which may alarm many adolescents.
4.5. Diagnostic radiation
Since IBD runs a relapsing and remitting course and requires
repeated endoscopic and radiological evaluations, patients
are frequently exposed to high levels of diagnostic radiation.
A retrospective cohort of 409 patients with Crohn's disease,49
identified age at diagnosis under 17 years as a specific risk
factor for exposure to more than 75 mSv of diagnostic
radiation (equivalent to three abdominal CT scans), a level
Table 1 Differences between children and adults, and paediatric and adult services in disease type, ideology of care, service
provision, approach to investigations, lifestyle and psychological distress that create barriers to successful transition and transfer in
IBD.
Children and paediatric services Adults and adult services
IBD More CD UC=CD
Extensive and severe UC and CD Frequently limited and ‘burnt-out’ disease
Limited disease duration (less than 5 years) Often longer disease duration
Disease course modification Management of flares and complications
Exclusive enteral diet main induction
treatment in CD
Prednisolone main induction treatment in CD
Body image concerns limit surgical options 80% patients undergo surgery by 10 years
Ideology Family-focused Patient-focused
Limited disease specific knowledge Well-informed
Parental decision making Individual decision making
Passive role with little autonomy Autonomy allows self-directed appointment booking,
nurse or telephone follow up
Lengthy appointments Business like, short appointments
Service Multidisciplinary approach Consultant led
Consultants with IBD subspecialty training Majority general gastroenterologists limited subspecialty
training
Tertiary centres Local hospitals
Access to research trial drug treatments Variable access to drug trials
High quality and age specific treatment areas Variable quality and not age specific treatment areas
Investigations Diagnostic tests frequently conducted under GA Diagnostic tests with conscious or no sedation
High risk of radiation induced malignancy
(USS/MRI)
Radiation risk probably less
Ability to screen for pubertal delay and growth
failure
Limited knowledge of developmental delay and or
growth failure
Oral and upper GI complications Surveillance for secondary conditions
(cancer/osteoporosis/anaemia)
Lifestyle Sexual experimentation Awareness of fecundity, contraception and family planning
Cigarette/alcohol/drug experimentation Smoking cessation
Exam pressures Career progression
Employment/higher education demands Becoming a parent
Psychological
distress
Anxiety and depression common Association with active disease
Suicide more common general population
513Transition of care in IBDthat reportedly increases the risk of a cancer related death
by 7.3%.50,51 It is conceivable that seeing patients in a young
adult clinic where physicians are used to re-investigating
patients may reduce cumulative exposure to diagnostic
radiation. In support of this, our own comparative study
demonstrated that adolescents received no more diagnostic
radiation than adults matched for disease duration, despite
having more extensive and severe disease. In addition they
were more likely to have been investigated with MRI than
adults.74.6. Psychological support
Cognitive behavioural therapy (CBT) aims to modify coping
strategies, improves mood and quality of life (QOL) scores
and may improve the clinical course of IBD itself.52,53 About
one third of adult IBD patients would like access topsychological support54 however this treatment is offered
in only 2% of UK IBD centres.46 This is partly because of a
perceived lack of benefit by adult gastroenterologists, but
also because CBT requires multiple, often inconvenient and
not inexpensive visits to a therapist. In contrast child
psychologists are an integral part of the paediatric multi-
disciplinary team, and although not evidence based are
recommended as part of the transition setup.
No studies have been designed to assess the experience of
young people during transition in IBD. Extrapolations of
results of studies using qualitative methods from other
chronic medical disorders including; cystic fibrosis,55 juve-
nile diabetes56 congenital heart disease (CHD),57,58 sickle
cell anaemia59 and organ transplantation recipients60,61
need to be interpreted with care due to the differences in
associated mortalities and disease course. However, the
obstacles to transition identified in these studies are thought
to be generic and likely to exist in IBD.17
514 J. Goodhand et al.5. Generic barriers to transition
Paediatric caregivers are often reluctant to relinquish their
patient's care: about a third of paediatric diabetes centres and
cystic fibrosis units reportedly continuing to care for patients
over the age of 25.62,63 Similarly, qualitative data suggest that
children and their parents are frequently reluctant to break
the familiar relationship with their paediatrician who they
have often known since diagnosis,56,57,60,61 and report anxiety
about joining a new healthcare team that are not appropri-
ately informed of their history.55,60,64 In particular, patients
with cystic fibrosis and their parents reported frustration at
the inflexibility of the legislatively determined age of
transfer.56 Adolescents frequently criticised the lack of
information provided,56,57,60 and suggested opportunities to
meet new healthcare teams and visits to adult-oriented
venues prior to transfer as a way of improving the transition
process.64 One qualitative theme identified in several studies
was that teenagers like being treated as adults, and prefer
healthcare staff to address them instead of their par-
ents.60,61,64 In this young age group few adult or paediatric
gastroenterologists directly address the issues of social drug
use or safer sex relationships. Data from transplant recipients
suggest that teenagers would value this information though do
they not want to ask directly for it.605.1. Disease specific knowledge
To pursue employment and fulfil education commitments
adolescents with IBD, like those with other chronic illnesses56
are often highly mobile and frequently change their address
and treating physician. Adolescent patients have been
criticised by adult gastroenterologists for not taking an
interest in their disease or responsibility for their own care.
Recent data fromToronto suggests that this pejorative opinion
is justified.65 Only 22% of adolescent patients could recall the
location of their disease and only 55% could recall when they
were diagnosed. Perhaps more surprisingly, their parent's
knowledge was not significantly better, although they could
recall which insurance company was paying for the care.
Although little data suggests that disease specific knowledge
influences disease activity or rates of relapse,39 it is crucial for
adult gastroenterologists who need to make treatment de-
cisions based on previous history. In order to improve lines of
communication between different treating physicians and as
part of the ‘The Good 2 Go Transition Program’ established at
the Hospital for Sick Children (SickKids) in Toronto,66 a
handheld synopsis of their condition, called the MyHealth
passport67 has been developed for adolescents. This simple
card details the pertinent IBD history and fits into a wallet, it
remains to be seen whether adolescents will use these or
other, for example electronic reminders and whether they
improve knowledge, drug adherence, or clinic attendance.6. Consequences of failed transition
Transition aims to educate the patient and their parents so
that they are ready for transfer to adult services and to
ensure that the ongoing healthcare provider is sufficiently
informed about the past and current problems so as toprovide continuity of care. An inadequate transition process
results in delayed and inappropriate care, improper timing of
transfer, and undue emotional and often financial stress for
patients, their families, and the health care system.68 Non-
specific measures such as lost to follow-up, admission and
medication non-adherence rates can be used as surrogate
markers to assess the efficacy of transition services.
6.1. Lost to follow-up rates
More than 90% children born with congenital heart disease
(CHD) survive to adulthood.69 Surprisingly, 75% are not
followed up in adult life, despite the increased risk of
morbidity associated with endocarditis, secondary pulmo-
nary hypertension, arrhythmias and cardiac failure.69,70 A
study of 300 adolescents with CHD identified ‘perceived
importance of follow up’, disease severity, older age,
independent paediatric outpatient visits, a lack of substance
abuse and adherence to antibiotic prophylaxis as factors
predictive of successful transfer.71 To our knowledge there is
no population data available to support a similar ‘lost tribe’
of young patients with IBD.72
6.2. Admission rates
Further evidence that adolescence is a vulnerable time in
patients with chronic diseases, comes from a study of
patients with CHD using insurance database records demon-
strating that the proportion of patients admitted via the
emergency department nearly doubled at the time of
transfer to adult care.73 Similarly, in a recent study of
adolescents with diabetes, hospitalisation rates increased
from 7.6 to 9.5 cases per 100 patient-years in the 2 years
after transfer to adult care. Previous DM-related hospitalisa-
tions, lower income, female gender, and living in areas with
low physician supply were associated with higher admission
rates. In support of stable transition care, individuals who
were transferred to a new allied health care team with no
change in physician were 20% less likely to be hospitalised
after the transition than were those transferred to a new
physician with either a new or no allied health care team.74
In our own study of adolescents with IBD ‘Did not attend’
(DNA) rates and hospital admissions were significantly
greater in the adolescent than matched adult group.7 School,
university and employment commitments may make daytime
clinic appointments inconvenient, and patients may not
appreciate the need for regular follow up especially when
their condition is inactive. What is not clear from our
admission data is the extent to which the increased
admission rate in adolescent patients reflects severity of
disease versus difficulties in accessing adult care services.
6.3. Adherence
Adherence is defined by the WHO as the extent to which a
person's behaviour (taking a medication, following a diet,
and/or executing life style changes) corresponds with agreed
recommendations from a health care provider.75 Evidence
from other medical disciplines suggests that adherence to
medications during transition is variable. Adolescent trans-
plant patients have non-adherence rates (defined using
Table 2 Adolescent and disease specific milestones that
determine the ‘ideal’ timing of transfer to adult care.
Determinant Ideal
Chronological age Between 16 and 25
Maturity Mature (role self-efficacy
scales)
Independent in health care No longer reliant on parents
Self-advocacy Ability to make informed
decisions
Preparation Knowledgeable
Readiness Comfortable with adult care
team
Availability of adult
specialist
Specialist interest in adolescent
IBD
Current medical status Clinical remission
Adherence to treatment Adherent even in remission
515Transition of care in IBDvariability of serum immunosuppressant levels) of up to
70%.76 Likewise adolescents with diabetes show a reduction
in glycaemic control as assessed by glycosylated haemaglobin
(HbA1c) levels at the point of transfer to adult care.77,78 The
factors underpinning adherence to IBD medications are
complex and poorly understood. Time constraints, medica-
tion side effects, poorly controlled disease activity and the
perception that the drug is not working,79 as well as simply
forgetting have been cited by adolescents with IBD and their
parents as reasons for non-adherence in IBD.80 In contrast,
factors that predict good adherence include shorter disease
duration, greater maternal involvement in the medical
regimen and higher perceived disease severity.81 In keeping
with this we have reported better apparent adherence to
thiopurine therapy in children and than adults in two
different case-controlled studies.7,82
7. Supportive evidence for structured transition
Whilst unproven, it is postulated that transition programmes
that inform patients about the rationale for ongoing follow-
up and teach them how to navigate the medical system may
avoid unnecessary admissions and improve adherence.72 To
date, no large scale prospective study has compared
outcomes of transfer, with or without a structured transition
programme in IBD.14 However, a pilot educational pro-
gramme for adolescent liver transplant recipients reported a
significant reduction in the previously documented variation
of serum immunosuppressant levels in association with a
reduction in elevated liver enzymes.83 Likewise, structured
transition in diabetes has been reported to improve
glycaemic control.78 In addition to a significant reduction
in HbA1c, specialist nurse transition facilitators that coordi-
nate outpatient visits and telephone based education
reduced both the number and duration of admissions for
diabetic keto-acidosis.84 Finally, an age-adjusted structured
transition programme improved QOL in both patients with
juvenile arthritis and their parents.85
8. Approaches to transition in IBD
In order to develop a successful model for transition in IBD,
one must take account of differences in maturity, disease
phenotype between childhood onset and adult onset IBD and
the services provided for the different age groups.86
Unfortunately the lack of comparative studies means that
no specific model can yet be recommended.
8.1. Types of transition reported in IBD
The simplest method of transfer is the use of a detailed
handover letter or discharge summary. Although inexpen-
sive, anecdotal reports suggest that this form of abrupt
transfer causes unnecessary harm, insufficient confidence in
parents and frustration in the adult gastroenterologist.87
Limited uncontrolled data suggest that a single one-hour
joint clinic where paediatricians introduce the adolescent to
the adult team and handover care in detail is sufficient with
85% patients and 74% parents reporting being ready to
transfer.88 Similar positive feedback has been reported bypatients attending several joint-run clinics.89 However,
there are relatively few paediatric gastroenterologists and
most are clustered together in city teaching hospitals. One
solution might be to create a managed clinical network
ensuring that clinicians can have the appropriate training
and facilities to care for this age group as close to home as is
possible.
8.2. Timing of transfer
Not all patients psychologically adapt to IBD in the same way,
some will be mature enough to transfer at 16, but others may
need to stay in transition care much longer. The factors
determining the timing of transfer are outlined in Table 2.
Wherever possible the timing of transfer to adult services
should be adjusted to the maturity of the individual.
Unfortunately not all healthcare providers allow this flexibility
and insist upon transfer at a predefined chronological age.90 As
in juvenile rheumatological disorders,91 independence/self-
efficacy scales have been developed, but not yet validated in
paediatric IBD (‘IBD-yourself’).92 In the future, these psycho-
metric tools may allow an objective measurement of maturity
to determine when transfer is most appropriate.
8.3. Transition at Barts and the London NHS Trust
Barts and the London NHS Trust in the East End of London is a
tertiary centre for adult and paediatric IBD, providing care to
about 2500 patients. In 2004, we instigated a weekly multi-
disciplinary meeting with adult and paediatric gastroenterol-
ogists, surgeons and allied health care professionals in
attendance where complex cases are discussed to allow
input from adult physicians into decisions on children who
would shortly transfer to their care.93 Alongside this 3 monthly
stand alone transition clinics where adult IBD specialists sat in
clinic with paediatric colleagues were initiated.
In 2005, following the publication of ‘National Standards
Framework (NSF) for Children, Young People and Maternity
services’which stated that transition must be clearly defined
for all children with chronic illnesses in the UK,11 we set up a
regular joint outpatient clinic. In brief, a paediatrician and
516 J. Goodhand et al.paediatric specialist IBD nurses attend a bi-weekly joint
clinic for adolescents with IBD with an adult gastroenterol-
ogist. Our patients are seen by either an adult gastroenter-
ologist or a paediatrician, with trainees from both specialties
in attendance. The clinics run at the same time as our
biologic infusion clinic and there is also access to a dietitian
and psychologist (Fig. 2).
This approach yields benefits for the patient as well as the
paediatric and adult gastroenterologist. For the patient,
continuity of care is seamless: patients attend clinic albeit
held in adult outpatients where they see familiar faces,
including their paediatric IBD specialist nurse, who co-
ordinates transition care. Furthermore as there are many
other patients in clinic of a similar age, patients can
appreciate that 'they are not alone' and mentors are easily
identified. For the paediatric gastroenterologist, this ex-
tended period of transition care reduces the importance of
transfer during a period of remission as they can continue the
care of adolescents whilst gradually introducing them to
the adult service. In addition, paediatricians are able to see
the future impact of management decisions made in the
paediatric clinic and can become more familiar with the
decision making process in adult gastroenterology to inform
the expectations of subsequent patients. The key advantages
of this approach for the adult gastroenterologist is that it
increases understanding of the paediatric approach to
decision making and allows sufficient time to become
familiar with several years of medical history during
paediatric follow up. We have found too that it stimulates
research and recruitment to clinical trials.
In the last 5 years during which we have cared for 500
adolescents in this clinic, feedback from the children and
families has been very positive. Not all patients wished to beAdult
gastroenterologist
Paediatric
gastroenterologist
Figure 2 Facilitators of extended transition in IBD. A
schematic diagram that highlights the importance of multi-
disciplinary care in adolescent patients with IBD undergoing
transition. This can be used to explain the roles of members of
the multidisciplinary team to patients and their parents in clinic.seen in the transition clinic preferring to immediately attend
a more local provider. In general these were patients with
relatively mild and easily controlled disease, those with the
more severe disease were reassured in attending a specialist
adult IBD clinic at least until they had completed their
education or had settled in work. In terms of the provider this
is regarded as an adult clinic. What has made this most
effective and achievable is the co-localisation of large
paediatric and adult IBD services on one site, the IBD nurse
specialist crossing the adult and paediatric settings and the
very close working relationship of the adult and paediatric
gastroenterologists. For young patients with chronic disease
we would argue this is the ideal scenario. Many paediatric
units are in standalone Children's Hospitals separate from
adult services and so setting up of such clinics is much more
difficult to achieve. In these circumstances managed clinical
networks may ensure similar levels of care.
9. Conclusions
IBD diagnosed during childhood and adolescence is becoming
increasingly common and the disease itself tends to be more
extensive and severe than in adults. The adult gastroenter-
ologist inherits a group of patients many of whom may have
ongoing active inflammation, with extensive disease, that is
frequently refractory to medical treatments and may not be
amenable to surgery. High quality evidence guiding thera-
peutic decisions in this setting is often lacking as most studies
in IBD are conducted in adults. Differences in paediatric and
adult services create significant barriers to seamless transfer
of care, which need to be taken into account when planning
transition services. Although increasingly more approaches
to transition are being described, cost-benefit analyses are
required to determine the best model for transition care and
its optimal timing. Extended transition clinics facilitated by a
specialist IBD nurse, like the one we have devised, although
not evidence-based are conceptually attractive, since they
allow time for adolescent patients to adjust to their new
adult gastroenterologists whilst concurrently seeing their
paediatrician.
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